ArticleCancer cell international2026
High xCT expression indicates poor prognosis and chemoradiotherapy resistance in rectal cancer patients.
Article in Cancer cell international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundxCT/SLC7A11, an amino acid transporter, is implicated in various cancers. However, its role in rectal cancer remains unclear. This study aimed to explore its predictive value for prognosis and chemoradiotherapy response in rectal cancer patients. METHODS AND MATERIALS: xCT expression was assessed using immunohistochemistry and RT-qPCR, and its associations with clinicopathological features and prognosis were analyzed. Single-cell RNA sequencing data and the TIMER platform were used to examine xCT's correlation with immune cell infiltration. A prognostic nomogram model was developed and evaluated with ROC, calibration, and decision curve analysis. Cell proliferation and cytotoxicity assays were conducted to assess xCT's role in ferroptosis and chemoradiotherapy sensitivity.
resultsxCT expression was elevated in rectal cancer tissues and correlated with adverse clinicopathological features, including tumor regression grade (P < 0.001). Single-cell and immune infiltration analyses indicated that xCT was associated with the immune microenvironment. High xCT expression predicted worse overall and disease-free survival, and multivariate analysis confirmed it as an independent prognostic factor. The xCT-based nomogram accurately predicted 1- and 3-year survival rates. Additionally, xCT knockout inhibited cell proliferation and enhanced chemoradiotherapy sensitivity in vitro and in vivo by promoting ferroptosis.
conclusionHigh expression of xCT was associated with poor prognosis and chemoradiotherapy response in rectal cancer, representing a potential prognostic marker and therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.